Original Article
Brief Report
Severe Hypothyroidism Caused by Type 3 Iodothyronine Deiodinase in Infantile Hemangiomas
N Engl J Med 2000; 343:185-189July 20, 2000
- Article
Hemangiomas are the most common tumors of infancy, with a prevalence of 5 to 10 percent among one-year-olds. They are characterized by rapid growth in the first year of life, followed by involution and gradual regression by adolescence.1,2 We recently treated a three-month-old infant with massive hepatic hemangiomas and primary hypothyroidism who needed very high doses of thyroid hormone to restore euthyroidism and normal thyrotropin secretion. This finding suggested that the rate of degradation of thyroid hormone was accelerated. We subsequently identified high levels of type 3 iodothyronine deiodinase activity in the hemangioma tissue. This selenoenzyme, normally present in the brain and placenta, catalyzes the conversion of thyroxine to reverse triiodothyronine and the conversion of triiodothyronine to 3,3'-diiodothyronine, both of which are biologically inactive. We then retrospectively analyzed other patients with hemangiomas and identified additional patients with similar histories and other hemangiomas with type 3 iodothyronine deiodinase activity.
Case Report
A full-term baby boy was delivered at home after a normal pregnancy. The parents declined to have him undergo thyroid screening. At six weeks of age, he was brought to medical attention because of abdominal distention. Liver biopsy revealed a hepatic hemangioma. The serum thyrotropin concentration was 156 μU per milliliter (normal range, 0.3 to 6.2), and the serum free thyroxine concentration was low. The infant was treated with prednisolone (2 mg per kilogram of body weight per day orally) for the hemangioma and levothyroxine (37.5 μg per day orally). After 5 days of treatment, his serum thyrotropin concentration was 42 μU per milliliter, but 16 days later it had increased to 256 μU per milliliter.
At three months of age, the infant was hospitalized for respiratory distress and increasing abdominal distention. His pulmonary status deteriorated rapidly, leading to intubation and transport to the Vascular Anomalies Center at Children's Hospital in Boston. Physical examination revealed marked abdominal distention and hepatomegaly with palpable nodules; the thyroid gland was not enlarged. The patient had intermittent bradycardia and hypothermia (temperature as low as 34°C). Magnetic resonance imaging confirmed the presence of multiple hepatic hemangiomas (Figure 1Figure 1
Frontal (Panel A) and Lateral (Panel B) Magnetic Resonance Images of the Abdomen of an Infant with Multiple Hepatic Hemangiomas and Hypothyroidism.). An echocardiogram showed depressed biventricular function (a left ventricular shortening fraction of 27 percent) with a patent foramen ovale and mild tricuspid and mitral regurgitation. The bone age was normal. The serum sodium concentration was 131 mmol per liter, the serum thyrotropin concentration was 177 μU per milliliter, the serum thyroxine concentration was 2.5 μg per deciliter (32 nmol per liter), the serum triiodothyronine concentration was less than 15 ng per deciliter (0.23 nmol per liter), the serum reverse triiodothyronine concentration was 413 ng per deciliter (6.36 nmol per liter), and the serum thyroglobulin concentration was 1014 ng per milliliter (normal range, 6 to 87) (Figure 2Figure 2
Thyroid Function and Treatment during Hospitalization in an Infant with Multiple Hepatic Hemangiomas.).3,4 The initial diagnosis was primary hypothyroidism, presumably congenital, complicated by noncompliance with treatment or impaired absorption of levothyroxine. Methylprednisolone was substituted for prednisolone, and interferon alfa-2b was added to the treatment regimen. The patient's respiratory compromise was thought to be due to hepatomegaly. Emergency embolization and surgery were considered, but the operative risk was deemed unacceptable given the severity of the hypothyroidism. Intravenous administration of liothyronine was initiated in order to correct the hypothyroidism rapidly, and this treatment reduced the infant's serum thyrotropin concentration to 79 μU per milliliter over a period of 26 hours (Figure 2), corrected the hyponatremia, and improved cardiac contractility. A continuous intravenous infusion of liothyronine was begun in doses of 24 to 96 μg per day, to which was added intravenous, and later nasojejunal, levothyroxine in doses of 30 to 50 μg per day. This treatment ultimately lowered serum thyrotropin concentrations to normal and raised serum triiodothyronine concentrations to normal, but serum thyroxine concentrations remained low (Figure 2). Serum reverse triiodothyronine concentrations were elevated at the time of presentation, fell with the initiation of the liothyronine infusion, and then rose once again to abnormal levels after the reintroduction of levothyroxine (Figure 2).
On the fourth day of hospitalization, a vertical midline abdominal fasciotomy was performed with the patient under general anesthesia. Two days later, multiple hemangiomas were embolized by hepatic-artery catheterization. Despite transient improvement, the infant remained dependent on mechanical ventilation. The doses of methylprednisolone and interferon alfa-2b were increased, but tumor growth continued. Staphylococcal bacteremia was diagnosed on day 19 of hospitalization. The infection responded to antibiotic therapy, but the infant's clinical status continued to worsen. Liver transplantation was considered and declined by his parents. At their request, he was transferred to a hospital in his home state on day 34. Oliguric renal failure developed six days later, and he died. An autopsy limited to the collection of hemangioma tissue was permitted by the parents.
The cause of this infant's hypothyroidism was still unclear at the time of his death. The high serum thyroglobulin concentration indicated the stimulation of endogenous thyroid tissue.5 In adults, the rate of production of triiodothyronine is approximately 32 μg per day.6 By comparison, in this 6.5-kg infant, a daily intravenous dose of up to 96 μg of liothyronine plus 30 to 50 μg of levothyroxine led only to a low-normal serum triiodothyronine concentration and did not increase the serum thyroxine concentration (Figure 2), indicating that the rate of degradation of both hormones was excessively high.
Monodeiodination of the inner ring of thyroxine and triiodothyronine catalyzed by type 3 iodothyronine deiodinase is the chief means of inactivating these hormones, producing reverse triiodothyronine and 3,3'-diiodothyronine, respectively. An increase in the activity of this enzyme could explain the marked increase in serum reverse triiodothyronine concentrations in the infant during treatment with levothyroxine infusion (Figure 2). Because hypothyroidism was present before interferon alfa-2b was given and worsened in parallel with the growth of the tumors, destruction of thyroid hormone by the hemangiomas or induction of type 3 iodothyronine deiodinase activity by a tumor product was suspected.
Methods
Tissue Preparation
A review of patients' charts and studies of human tissue were approved by the investigative review board of the hospital. Placental tissue was obtained at term from a woman with no known medical problems. Frozen specimens of hemangioma tissue were recovered from storage at –80°C. Tissue homogenates were suspended in a buffer of 0.1 M phosphate and 1 mM EDTA at pH 6.9 with 10 mM dithiothreitol and 0.25 M sucrose for enzyme analysis or in Trizol reagent (Life Technologies, Rockville, Md.) to isolate RNA.7
Type 3 Iodothyronine Deiodinase Assays
Each deiodination reaction included 3 to 150 μg of cellular protein, 200,000 cpm of 3,3',[125I]5'-triiodothyronine (New England Nuclear, Boston), 0 or 1 mM 6N-propylthiouracil, 10 mM dithiothreitol, and various concentrations of unlabeled triiodothyronine. The reaction was stopped by the addition of ethanol. The labeled substrate and deiodination products were quantified by paper chromatography, and iodothyronines were identified by colorimetry.7
Northern Blot Analysis
For the Northern blot analysis, total RNA was isolated with Trizol reagent according to the manufacturer's recommendations. A Northern blot was prepared according to standard methods and probed with a 1.1-kb fragment of human type 3 iodothyronine deiodinase complementary DNA. Relative to the start codon, this fragment included nucleotides –35 to 849.7 The blot was stripped and reprobed with rat cyclophilin to adjust for differences in the loading and transfer of the samples.
In Situ Hybridization
For in situ hybridization, 12-μm frozen sections were cut with a cryostat (Leica, Allendale, N.J.) and fixed with 4 percent paraformaldehyde in phosphate-buffered saline. A complementary-RNA probe was prepared that included the same sequences that were used in the Northern blot analysis, and in situ hybridization was performed in which 2×107 to 3×107 cpm of probe per milliliter was hybridized with the specimens at 65°C for 16 to 20 hours.
Retrospective Review of Patients with Hemangioma
A list of patients with hemangiomas who were seen at Children's Hospital between January 1993 and December 1999 was obtained. Patients were included if they had been given a diagnosis of hemangioma (International Classification of Diseases, 9th Revision, codes 228.00 through 228.04 and code 228.09). For each patient, the results of thyroid-function tests were retrieved from computerized laboratory records.
Results
Analysis of Type 3 Iodothyronine Deiodinase Activity in Hemangioma Tissue from the Patient
The patient's hemangioma exhibited type 3 iodothyronine deiodinase activity that was insensitive to incubation with 6N-propylthiouracil, with a Michaelis constant of 2.5 nM for triiodothyronine. The maximal velocity of the activity was 0.78 pmol of triiodothyronine deiodinated per minute per milligram of protein, a value 7.5 times that in placental tissue, which has the highest level of activity under normal circumstances (Figure 3AFigure 3
Results of Analysis of Type 3 Iodothyronine Deiodinase Activity and Pathological Studies.).7 The type 3 iodothyronine deiodinase complementary-DNA probe hybridized to a single RNA band of approximately 2.2 kb in the hemangioma and placental tissues (data not shown). The ratio of the density of type 3 iodothyronine deiodinase messenger RNA to the density of cyclophilin messenger RNA in the patient's hemangioma tissue was 3.6 times the ratio in placental tissue. In situ hybridization showed that type 3 iodothyronine deiodinase messenger RNA originated from hemangioma cells (Figure 3B and Figure 3C).Retrospective Review of Patients and Analysis of Type 3 Iodothyronine Deiodinase Activity in Hemangioma Tissue from Other Patients
Among the 1555 patients with hemangiomas whom we identified, serum thyrotropin had been measured in 92 (6 percent), most of whom were scheduled to receive interferon, which can cause thyroid dysfunction.8 Nine patients had values that were high for their age.9 Excluding the index patient, three patients had serum thyrotropin concentrations that were more than twice the upper limit of the normal range. One was considered to have congenital hypothyroidism. The other two had had normal results on thyroid screening as newborns and were considered to have acquired hypothyroidism. Like our patient, both had massive hepatic hemangiomas, low serum thyroxine concentrations, and high serum thyrotropin concentrations (567 μU per milliliter at the age of 3 months in one patient and 88 μU per milliliter at the age of 2 2 /3 years in the other). Hemangioma tissue from these patients was not available for study.
Samples of hemangioma tissue from five other patients were available and were assayed for type 3 iodothyronine deiodinase activity. Three of these specimens had type 3 iodothyronine deiodinase activity, with velocities of 0.017 pmol of triiodothyronine deiodinated per minute per milligram of protein in the case of a hepatic hemangioma specimen and of 0.014 and 0.042 pmol of triiodothyronine deiodinated per minute per milligram of protein in the case of two cutaneous hemangioma specimens, as compared with a velocity of 0.038 pmol of triiodothyronine deiodinated per minute per milligram of protein in the case of placental tissue analyzed at the same time.
Discussion
Our patient had severe biochemical hypothyroidism in association with massive hepatic hemangiomas and required very high doses of levothyroxine and liothyronine to reduce serum thyrotropin concentrations to normal. Athyrotic infants who are the same age as our patient usually require about 7 μg of oral levothyroxine per kilogram daily to restore serum thyrotropin concentrations to normal, whereas our patient required approximately eight to nine times as much, including the daily dose of liothyronine and assuming that 40 percent of the exogenous thyroxine is converted to triiodothyronine.6,10,11
An accelerated rate of inactivation of thyroid hormone by type 3 iodothyronine deiodinase in the hemangioma is the best explanation of this phenomenon, with the enzymatic activity of the tumor, because of its large mass and vascularity, exceeding the synthetic capacity of the infant's thyroid. The presence of a similar, although less severe, abnormality presumably also explains the acquired hypothyroidism in the other two patients we identified. The finding of type 3 iodothyronine deiodinase activity in three of five other hemangioma specimens that we tested indicates that its presence in our patient's hemangioma is not unique. The two other types of iodothyronine deiodinase act primarily on the outer iodothyronine ring, and they have a weak capacity (in the case of type 1) to remove iodine to an inner ring or are unable to do so (in the case of type 2).6
The proliferative phase of hemangiomas is characterized by the increased expression of angiogenic factors such as basic fibroblast growth factor.1,12 In neonatal glial cells or brown adipocytes from rats, the activity of type 3 iodothyronine deiodinase or the expression of its messenger RNA is increased by incubation with fibroblast growth factors, because these factors activate the extracellular receptor kinase pathway.13-16 It seems likely that the high level of expression of type 3 iodothyronine deiodinase in hemangiomas is due to the endocrine or paracrine induction of the enzyme in endothelial cells by basic fibroblast growth factor or other growth factors.
In the first year of life, approximately three to five IQ points are lost for each month in which hypothyroidism remains untreated.17 This developmentally critical period corresponds to the proliferative phase of hemangiomas and arouses concern that infants with this tumor may be at risk for permanent neurologic damage. Infantile hypothyroidism is often occult, and even severe symptoms could be masked by complications of the hemangioma itself.17,18 Impaired hemostasis from hypothyroidism could confound the coagulopathy of hepatic failure or the Kasabach–Merritt syndrome.19 Cardiac impairment from hypothyroidism could exacerbate the congestive heart failure associated with high-flow hemangiomas.20,21 Even the later spastic diplegia and delayed myelination attributed to neurotoxicity induced by interferon in these patients are features of hypothyroidism in infants.22-24
The majority of hemangiomas are small and require no therapy.1,2 Given the adaptive capacity of the normal thyroid gland, it is likely that only patients with both high levels of type 3 iodothyronine deiodinase activity and large tumor burdens are at risk for hypothyroidism. Until prospective studies can better quantify this risk, thyroid function should be assessed in children with large hemangiomas before any type of therapy is begun and periodically thereafter, especially if symptoms of hypothyroidism appear or the tumor burden increases rapidly. If hypothyroidism is diagnosed, higher doses of levothyroxine may be needed.
Supported by grants (DK07699, DK07529, and DK44128) from the National Institutes of Health.
We are indebted to the parents of the index patient for allowing medical research to be conducted after his death; to Drs. Joseph Majzoub, David A. Weinstein, Antonio Bianco, and Joyce Bischoff for critically reviewing and discussing the manuscript; to Dr. Diego Jaramillo for reviewing the radiographic studies; and to Dr. Jerald C. Nelson of Quest Diagnostics (San Juan Capistrano, Calif.) for performing reverse triiodothyronine assays on frozen serum samples.
Source Information
From the Division of Endocrinology (S.A.H., M.V., A.J.B.), the Departments of Pathology and Pediatrics (H.P.W.K.), and the Department of Surgery and the Vascular Anomalies Center (S.J.F.), Children's Hospital; and the Thyroid Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School (H.M.T., J.W.H., P.R.L.) — all in Boston.
Address reprint requests to Dr. Larsen at the Thyroid Division, Harvard Medical School, Rm. 560, Harvard Institutes of Medicine, 77 Ave. Louis Pasteur, Boston, MA 02115, or at larsen@rascal.med. harvard.edu.
- References
References
1
Drolet BA ,Esterly NB ,Frieden IJ . Hemangiomas in children. N Engl J Med 1999;341:173-181
Full Text | Web of Science | Medline2
Fishman SJ ,Muliken JB . Hemangiomas and vascular malformations of infancy and childhood. Pediatr Clin North Am 1993;40:1177-1200
Web of Science | Medline3
Ket JL ,De Vijder JJ ,Bikker H ,Gons MH ,Tegelaers WH . Serum thyroglobulin levels: the physiological decrease in infancy and the absence in athyroidism. J Clin Endocrinol Metab 1981;53:1301-1303
CrossRef | Web of Science | Medline4
Chopra IJ ,Sack J ,Fisher DA . Circulating 3,3',5'-triiodothyronine (reverse T3) in the human newborn. J Clin Invest 1975;55:1137-1141
CrossRef | Web of Science | Medline5
Ostergaard GZ ,Jacobsen BB . Atrophic, autoimmune thyroiditis in infancy: a case report. Horm Res 1989;31:190-192
CrossRef | Web of Science | Medline6
Larsen PR, Davies TF, Hay ID. The thyroid gland. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams textbook of endocrinology. 9th ed. Philadelphia: W.B. Saunders, 1998:389-515.
7
Salvatore D ,Low SC ,Berry M , et al. Type 3 iodothyronine deiodinase: cloning, in vitro expression, and functional analysis of the placental selenoenzyme. J Clin Invest 1995;96:2421-2430
CrossRef | Web of Science | Medline8
Koh LK ,Greenspan FS ,Yeo PP . Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997;7:891-896
CrossRef | Web of Science | Medline9
Zurakowski D ,Di Canzio J ,Majzoub JA . Pediatric reference intervals for serum thyroxine, triiodothyronine, thyrotropin, and free thyroxine. Clin Chem 1999;45:1087-1091
Web of Science | Medline10
Mandel SJ ,Brent GA ,Larsen PR . Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993;119:492-502
Web of Science | Medline11
Germak JA ,Foley TP Jr . Longitudinal assessment of L-thyroxine therapy for congenital hypothyroidism. J Pediatr 1990;117:211-219
CrossRef | Web of Science | Medline12
Takahashi K ,Mulliken JB ,Kozakewich HP ,Rogers RA ,Folkman J ,Ezekowitz RA . Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994;93:2357-2364
CrossRef | Web of Science | Medline13
Hernandez A ,St Germain DL ,Obregon MJ . Transcriptional activation of type III inner ring deiodinase by growth factors in cultured rat brown adipocytes. Endocrinology 1998;139:634-639
CrossRef | Web of Science | Medline14
Courtin F ,Liva P ,Gavaret JM ,Toru-Delbauffe D ,Pierre M . Induction of 5-deiodinase activity in astroglial cells by 12-O-tetradecanoylphorbol 13-acetate and fibroblast growth factors. J Neurochem 1991;56:1107-1113
CrossRef | Web of Science | Medline15
Pallud S ,Ramauge M ,Gavaret JM , et al. Regulation of type 3 iodothyronine deiodinase expression in cultured rat astrocytes: role of the Erk cascade. Endocrinology 1999;140:2917-2923
CrossRef | Web of Science | Medline16
Hernandez A ,Obregon MJ . Presence of growth factors-induced type III iodothyronine 5-deiodinase in cultured rat brown adipocytes. Endocrinology 1995;136:4543-4550
CrossRef | Web of Science | Medline17
Fisher DA . Management of congenital hypothyroidism. J Clin Endocrinol Metab 1991;72:523-529
CrossRef | Web of Science | Medline18
LaFranchi S . Congenital hypothyroidism: etiologies, diagnosis, and management. Thyroid 1999;9:735-740
CrossRef | Web of Science | Medline19
Myrup B ,Bregengard C ,Faber J . Primary haemostasis in thyroid disease. J Intern Med 1995;238:59-63
CrossRef | Web of Science | Medline20
Balducci G ,Acquafredda A ,Amendola F ,Natuzzi M ,Laforgia N ,Cavallo L . Cardiac function in congenital hypothyroidism: impairment and response to L-T4 therapy. Pediatr Cardiol 1991;12:28-32
CrossRef | Web of Science | Medline21
Ladenson PW ,Goldenheim PD ,Ridgway EC . Rapid pituitary and peripheral tissue responses to intravenous L-triiodothyronine in hypothyroidism. J Clin Endocrinol Metab 1983;56:1252-1259
CrossRef | Web of Science | Medline22
Barlow CF ,Priebe CJ ,Mulliken JB , et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998;132:527-530
CrossRef | Web of Science | Medline23
Deb G ,Jenkner A ,Donfrancesco A . Spastic diplegia and interferon. J Pediatr 1999;134:382-382
CrossRef | Web of Science | Medline24
Worle H ,Maass E ,Kohler B ,Treuner J . Interferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication. Eur J Pediatr 1999;158:344-344
CrossRef | Web of Science | Medline
- Citing Articles (74)
Citing Articles
1
Derek Roebuck, Neil Sebire, Eldon Lehmann, Alex Barnacle. (2012) Rapidly involuting congenital haemangioma (RICH) of the liver. Pediatric Radiology
CrossRef2
Sureka Bollepalli, Susan R. Rose. 2012. Disorders of the Thyroid Gland. , 1307-1319.
CrossRef3
Ann M. Kulungowski, Ahmad I. Alomari, Aditya Chawla, Emily R. Christison-Lagay, Steven J. Fishman. (2012) Lessons from a liver hemangioma registry: subtype classification. Journal of Pediatric Surgery 47:1, 165-170
CrossRef4
Liese Mebis, Greet Van den Berghe. (2011) Thyroid axis function and dysfunction in critical illness. Best Practice & Research Clinical Endocrinology & Metabolism 25:5, 745-757
CrossRef5
Arin K. Greene, Allen S. Liu, John B. Mulliken, Kimberly Chalache, Steven J. Fishman. (2011) Vascular anomalies in 5621 patients: guidelines for referral. Journal of Pediatric Surgery 46:9, 1784-1789
CrossRef6
Anna L. Bruckner, Ilona J. Frieden. 2011. Infantile Haemangiomas and Other Vascular Tumours. , 113.1-113.28.
CrossRef7
Iwei Yeh, Anna L. Bruckner, Rosa Sanchez, Michael R. Jeng, Brandon D. Newell, Ilona J. Frieden. (2011) Diffuse Infantile Hepatic Hemangiomas: A Report of Four Cases Successfully Managed with Medical Therapy. Pediatric Dermatology 28:3, 267-275
CrossRef8
Kimberly A. Horii, Beth A. Drolet, Ilona J. Frieden, Eulalia Baselga, Sarah L. Chamlin, Anita N. Haggstrom, Kristen E. Holland, Anthony J. Mancini, Catherine C. McCuaig, Denise W. Metry, Kimberly D. Morel, Brandon D. Newell, Amy J. Nopper, Julie Powell, Maria C. Garzon, . (2011) Prospective Study of the Frequency of Hepatic Hemangiomas in Infants with Multiple Cutaneous Infantile Hemangiomas. Pediatric Dermatology 28:3, 245-253
CrossRef9
Nedim Hadzic, Milton J. Finegold. (2011) Liver Neoplasia in Children. Clinics in Liver Disease 15:2, 443-462
CrossRef10
Karen F. Murray, Laura S. Finn. 2011. Neoplasms of the Gastrointestinal Tract and Liver. , 528-539.
CrossRef11
Masatoshi JINNIN, Tsuyoshi ISHIHARA, Eileen BOYE, Bjorn R. OLSEN. (2010) WITHDRAWN; Recent progress in studies of infantile hemangioma. The Journal of Dermatology 37:11, 939-955
CrossRef12
Emerson L Olivares, Denise P Carvalho. (2010) Thyroid hormone metabolism in heart failure: iodothyronine deiodinases in focus. Current Opinion in Endocrinology, Diabetes and Obesity 17:5, 414-417
CrossRef13
Paula E. North. (2010) Pediatric Vascular Tumors and Malformations. Surgical Pathology Clinics 3:3, 455-494
CrossRef14
RA Schwartz, MI Sidor, ML Musumeci, RL Lin, G Micali. (2010) Infantile haemangiomas: a challenge in paediatric dermatology. Journal of the European Academy of Dermatology and Venereology 24:6, 631-638
CrossRef15
Masatoshi JINNIN, Tsuyoshi ISHIHARA, Eileen BOYE, Bjorn R. OLSEN. (2010) Recent progress in studies of infantile hemangioma. The Journal of Dermatology 37:4, 283-298
CrossRef16
Alexandra M. Dumitrescu, Caterina Di Cosmo, Xiao-Hui Liao, Roy E. Weiss, Samuel Refetoff. (2010) The Syndrome of Inherited Partial SBP2 Deficiency in Humans. Antioxidants & Redox Signaling 12:7, 905-920
CrossRef17
C. Moss, H. Shahidullah. 2010. Naevi and other Developmental Defects. , 1-107.
CrossRef18
Christine J. Pol, Alice Muller, Warner S. Simonides. (2010) Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: an adaptative response or part of the problem?. Heart Failure Reviews 15:2, 133-142
CrossRef19
Marie Merheb, Roula Hourani, Mira S. Zantout, Sami T. Azar. (2010) Endocrine Dysfunction in a Patient With Phace Syndrome, Including Port-Wine Stain of the Right Periorbital Area. Endocrine Practice 16:2, 255-259
CrossRef20
Kazuhiko Bessho, Yuri Etani, Hiroaki Ichimori, Yoko Miyoshi, Noriyuki Namba, Akihiro Yoneda, Takaharu Ooue, Tsuyoshi Chihara, Eiichi Morii, Tomoyuki Aoki, Masami Murakami, Sotaro Mushiake, Keiichi Ozono. (2010) Increased type 3 iodothyronine deiodinase activity in a regrown hepatic hemangioma with consumptive hypothyroidism. European Journal of Pediatrics 169:2, 215-221
CrossRef21
Aleksandar Vlahovic, Radoje Simic, Dragomir Djokic, Candemir Ceran. (2009) Diffuse Neonatal Hemangiomatosis Treatment With Cyclophosphamide. Journal of Pediatric Hematology/Oncology 31:11, 858-860
CrossRef22
Malgorzata Markiewicz-Kijewska, Weronika Kasprzyk, Dorota Broniszczak, Ludmila Bacewicz, Anna Ostoja-Chyzynska, Hor Ismail, Andrzej Kosciesza, Bozenna Dembowska-Baginska, Joanna Teisseyre, Przemyslaw Kluge, Grazyna Brzezinska-Rajszys, Irena Jankowska, Piotr Kalicinski. (2009) Hemodynamic failure as an indication to urgent liver transplantation in infants with giant hepatic hemangiomas or vascular malformations - Report of four cases. Pediatric Transplantation 13:7, 906-912
CrossRef23
Rosalind S. Brown. 2009. The Thyroid. , 250-282.
CrossRef24
Elisa Boscolo, Joyce Bischoff. (2009) Vasculogenesis in infantile hemangioma. Angiogenesis 12:2, 197-207
CrossRef25
Kui-ran Dong, Shan Zheng, Xianming Xiao. (2009) Conservative management of neonatal hepatic hemangioma: a report from one institute. Pediatric Surgery International 25:6, 493-498
CrossRef26
Ahmad I. Alomari. (2009) Comments on imaging and management of hepatic hemangiomas. Pediatric Radiology 39:6, 637-638
CrossRef27
Bram B. Meijs, Johannes H. M. Merks, Timo R. Haan, Merit M. Tabbers, Rick R. Rijn. (2009) Neonatal hepatic haemangioendothelioma: treatment options and dilemmas. Pediatric Radiology 39:3, 277-281
CrossRef28
Bridgette Guthrie. (2009) Vaginal Bleeding In the Prepubescent Child. Clinical Pediatric Emergency Medicine 10:1, 14-19
CrossRef29
Eileen Boye, Masatoshi Jinnin, Bjorn R. Olsen. (2009) Infantile Hemangioma. Journal of Craniofacial Surgery 20:Suppl 1, 678-684
CrossRef30
David A. Hartemink, Yvonne E. Chiu, Beth A. Drolet, Joseph E. Kerschner. (2009) PHACES syndrome: A review. International Journal of Pediatric Otorhinolaryngology 73:2, 181-187
CrossRef31
Warren R. Heymann. (2009) Hemangiomas and thyroid disease. Journal of the American Academy of Dermatology 60:1, 144-145
CrossRef32
Alessandro Mussa, Giuseppina Baldassarre, Lucia Rosaia De Santis, Roberto Gastaldi, Andrea Corrias, Margherita Cirillo Silengo. (2008) Four new cases of PHACES syndrome: variable phenotypic expression and endocrine features. Acta Paediatrica 97:12, 1729-1733
CrossRef33
Luciane P. Capelo, Eduardo H. Beber, Stephen A. Huang, Telma M.T. Zorn, Antonio C. Bianco, Cecília H.A. Gouveia. (2008) Deiodinase-mediated thyroid hormone inactivation minimizes thyroid hormone signaling in the early development of fetal skeleton. Bone 43:5, 921-930
CrossRef34
Yves Debaveye, Björn Ellger, Liese Mebis, Veerle M. Darras, Greet Van den Berghe. (2008) Regulation of Tissue Iodothyronine Deiodinase Activity in a Model of Prolonged Critical Illness. Thyroid 18:5, 551-560
CrossRef35
Denise M. Adams, Mary Sue Wentzel. (2008) The Role of the Hematologist/Oncologist in the Care of Patients with Vascular Anomalies. Pediatric Clinics of North America 55:2, 339-355
CrossRef36
Yoon Hi Cho, Craig Taplin, Albert Mansour, Robert Howman-Giles, Robert Hardwick, David Lord, Neville J Howard. (2008) Case report: consumptive hypothyroidism consequent to multiple infantile hepatic haemangiomas. Current Opinion in Pediatrics 20:2, 213-215
CrossRef37
Stephen A Huang, Antonio C Bianco. (2008) Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nature Clinical Practice Endocrinology & Metabolism 4:3, 148-155
CrossRef38
DELBERT A. FISHER, ANNETTE GRUETERS. 2008. Thyroid Disorders in Childhood and Adolescence. , 227-253.
CrossRef39
Keigo Osuga, Hiroki Higashihara, Noboru Maeda, Yuki Hata, Akihiro Yoneda, Shuichiro Uehara, Tetsuro Nakazawa, Kaname Tomoda, Hironobu Nakamura. (2008) Diagnosis and management of vascular anomalies of the head and neck. Toukeibu Gan 34:3, 393-397
CrossRef40
Ram Kalpatthi, John Germak, Katherine Mizelle, Nicholas Yeager. (2007) Thyroid abnormalities in infantile hepatic hemangioendothelioma. Pediatric Blood & Cancer 49:7, 1021-1024
CrossRef41
Farheen Shirazi, Cynthia Cohen, Levi Fried, Jack L. Arbiser. (2007) Mammalian Target of Rapamycin (mTOR) is Activated in Cutaneous Vascular Malformations in Vivo. Lymphatic Research and Biology 5:4, 233-236
CrossRef42
Carmen M. Barnés, Emily A. Christison-Lagay, Judah Folkman. (2007) The Placenta Theory and the Origin of Infantile Hemangioma. Lymphatic Research and Biology 5:4, 245-256
CrossRef43
Rebecka L. Meyers. (2007) Tumors of the liver in children. Surgical Oncology 16:3, 195-203
CrossRef44
Emily R. Christison-Lagay, Patricia E. Burrows, Ahmad Alomari, Josée Dubois, Harry P. Kozakewich, Tricia S. Lane, Harriet J. Paltiel, Giannoula Klement, John B. Mulliken, Steven J. Fishman. (2007) Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. Journal of Pediatric Surgery 42:1, 62-68
CrossRef45
Liese Mebis, Yves Debaveye, Theo J. Visser, Greet Van den Berghe. (2006) Changes Within the Thyroid Axis During the Course of Critical Illness. Endocrinology & Metabolism Clinics of North America 35:4, 807-821
CrossRef46
Kristianna M Pittman, H Wolfgang Losken, Mark E Kleinman, Jeffrey R Marcus, Francine Blei, Geoffrey C Gurtner, Douglas A Marchuk. (2006) No Evidence for Maternal–Fetal Microchimerism in Infantile Hemangioma: A Molecular Genetic Investigation. Journal of Investigative Dermatology 126:11, 2533-2538
CrossRef47
Anke Tönjes, Stefan Karger, Christian A. Koch, Ralf Paschke, Andrea Tannapfel, Michael Stumvoll, Dagmar Fuhrer. (2006) Impaired Enteral Levothyroxine Absorption in Hypothyroidism Refractory to Oral Therapy After Thyroid Ablation for Papillary Thyroid Cancer: Case Report and Kinetic Studies. Thyroid 16:10, 1047-1051
CrossRef48
Deborah S. Goddard, Marilyn G. Liang, Sarah L. Chamlin, Britta M. Svoren, Norman P. Spack, John B. Mulliken. (2006) Hypopituitarism in PHACES Association. Pediatric Dermatology 23:5, 476-480
CrossRef49
Jean Vanderpas. (2006) Nutritional Epidemiology and Thyroid Hormone Metabolism. Annual Review of Nutrition 26:1, 293-322
CrossRef50
D.W. Metry, A.N. Haggstrom, B.A. Drolet, E. Baselga, S. Chamlin, M. Garzon, K. Horii, A. Lucky, A.J. Mancini, B. Newell, A. Nopper, G. Heyer, I.J. Frieden. (2006) A prospective study of PHACE syndrome in infantile hemangiomas: Demographic features, clinical findings, and complications. American Journal of Medical Genetics Part A 140A:9, 975-986
CrossRef51
Emily R. Christison-Lagay, Steven J. Fishman. (2006) Vascular Anomalies. Surgical Clinics of North America 86:2, 393-425
CrossRef52
R PEETERS. (2006) Changes Within the Thyroid Axis During Critical Illness. Critical Care Clinics 22:1, 41-55
CrossRef53
Mary D. Ruppe, Stephen A. Huang, Suzanne M. Jan de Beur. (2005) Consumptive Hypothyroidism Caused by Paraneoplastic Production of Type 3 Iodothyronine Deiodinase. Thyroid 15:12, 1369-1372
CrossRef54
Donald L. St. Germain, Arturo Hernandez, Mark J. Schneider, Valerie Anne Galton. (2005) Insights Into the Role of Deiodinases from Studies of Genetically Modified Animals. Thyroid 15:8, 905-916
CrossRef55
Arturo Hernandez. (2005) Structure and Function of the Type 3 Deiodinase Gene. Thyroid 15:8, 865-874
CrossRef56
George G.J.M. Kuiper, Monique H.A. Kester, Robin P. Peeters, Theo J. Visser. (2005) Biochemical Mechanisms of Thyroid Hormone Deiodination. Thyroid 15:8, 787-798
CrossRef57
Antonio C. Bianco, P. Reed Larsen. (2005) Cellular and Structural Biology of the Deiodinases. Thyroid 15:8, 777-786
CrossRef58
Françoise Courtin, Hassan Zrouri, Audrey Lamirand, Wu Wen Li, Gilles Mercier, Michael Schumacher, Claude Le Goascogne, Michel Pierre. (2005) Thyroid Hormone Deiodinases in the Central and Peripheral Nervous System. Thyroid 15:8, 931-942
CrossRef59
Stephen A. Huang. (2005) Physiology and Pathophysiology of Type 3 Deiodinase in Humans. Thyroid 15:8, 875-881
CrossRef60
Shapour Omidvari, Nosrat Nezakatgoo, Niloofar Ahmadloo, Mohammad Mohammadianpanah, Ahmad Mosalaei. (2005) Role of Intralesional Bleomycin in the Treatment of Complicated Hemangiomas: Prospective Clinical Study. Dermatologic Surgery 31:5, 499-501
CrossRef61
Ayla Güven, Canan Aygun, Hülya NIL, Murat Aydın, F. Güçlü Pınarlı, Kemal Baysal, Sükrü Küçük.. (2005) Severe Hypothyroidism Caused by Hepatic Hemangioendothelioma in an Infant of a Diabetic Mother. Hormone Research 63:2, 86-89
CrossRef62
Caroline GP Roberts, Paul W Ladenson. (2004) Hypothyroidism. The Lancet 363:9411, 793-803
CrossRef63
Toshihide Yamamoto. (2003) Tablet Formulation of Levothyroxine Is Absorbed Less Well Than Powdered Levothyroxine. Thyroid 13:12, 1177-1181
CrossRef64
José C Moreno, Jan J.M de Vijlder, Thomas Vulsma, Carrie Ris-Stalpers. (2003) Genetic basis of hypothyroidism: recent advances, gaps and strategies for future research. Trends in Endocrinology & Metabolism 14:7, 318-326
CrossRef65
Arturo Hernandez, Donald L. St. Germain. (2003) Activity and response to serum of the mammalian thyroid hormone deiodinase 3 gene promoter: identification of a conserved enhancer. Molecular and Cellular Endocrinology 206:1-2, 23-32
CrossRef66
Arturo Hernandez, Donald L. St. Germain. (2003) Thyroid hormone deiodinases: physiology and clinical disorders. Current Opinion in Pediatrics 15:4, 416-420
CrossRef67
Michael B. Zimmermann, Josef Köhrle. (2002) The Impact of Iron and Selenium Deficiencies on Iodine and Thyroid Metabolism: Biochemistry and Relevance to Public Health. Thyroid 12:10, 867-878
CrossRef68
Judah Folkman. (2002) The Podium. The Journal of Law, Medicine & Ethics 30:3, 361-366
CrossRef69
L. A. Tannahill, T. J. Visser, C. J. McCabe, S. Kachilele, K. Boelaert, M. C. Sheppard, J. A. Franklyn, N. J. L. Gittoes. (2002) Dysregulation of iodothyronine deiodinase enzyme expression and function in human pituitary tumours. Clinical Endocrinology 56:6, 735-743
CrossRef70
Joanne E Langton, Gregory A Brent. (2002) Nonthyroidal illness syndrome: evaluation of thyroid function in sick patients. Endocrinology & Metabolism Clinics of North America 31:1, 159-172
CrossRef71
M. Murakami, M. Mori. 2002. Iodothyronine Deiodinase. .
CrossRef72
Ying Yu, Joyce Varughese, Lawrence F. Brown, John B. Mulliken, Joyce Bischoff. (2001) Increased Tie2 Expression, Enhanced Response to Angiopoietin-1, and Dysregulated Angiopoietin-2 Expression in Hemangioma-Derived Endothelial Cells. The American Journal of Pathology 159:6, 2271-2280
CrossRef73
Joyce Bischoff, and John B. Mulliken. (2001) Altered Mitochondrial Cytochrome b Gene Expression during the Regression of Hemangioma by Qurratulain Hasan, Ph.D., Swee T. Tan, M.B.B.S., F.R.A.C.S., Ph.D., Jason Gush, B.Sc., and Paul F. Davis, Ph.D.. Plastic and Reconstructive Surgery 108:6, 1477-1478
CrossRef74
Keira P. Mason, Babu V. Koka, Elizabeth A. Eldredge, Steven J. Fishman, Patricia E. Burrows. (2001) Perioperative considerations in a hypothyroid infant with hepatic haemangioma. Pediatric Anesthesia 11:2, 228-232
CrossRef
